title: AIDS-related primary brain lymphomas: histopathologic and immunohistochemical study of 51 cases. The French Study Group for HIV-Associated Tumors.
abstract: Fifty-one cases of acquired immunodeficiency syndrome (AIDS)-related primary brain lymphomas (AR-PBL) were investigated for clinical characteristics; human immunodeficiency virus (HIV)-associated disorders; histopathologic features; immunophenotype; Epstein-Barr virus (EBV) infection; and, when frozen tissue was available, oncogene rearrangements. AR-PBL occurred late in the course of AIDS and were usually associated with other systemic or cerebral disorders and with a low level of CD4 lymphocytes. All cases were high grade lymphomas according to the Working Formulation or updated Kiel classification, and often displayed a multifocal pattern. Thirty cases were classified as immunoblastic with plasmacytic differentiation, 18 cases were large cell lymphomas with an immunoblastic component or centroblastic polymorphic lymphomas, and 2 were small noncleaved non-Burkitt lymphomas (Working Formulation). This latter category is classified as Burkitt's-like lymphoma in the REAL nomenclature. One case could not be classified because of necrosis. AR-PBL showed a high level expression of activation and adhesion molecules. The presence of EBV was detected in most cases, and, when PCR was used, this was a constant finding. bcl-2 oncoprotein and latent membrane protein-1 (LMP-1) were strongly expressed. None of the tested cases expressed p53, or were rearranged for bcl-2 or c-myc oncogenes. This study confirms the immunophenotypic specificity of AR-PBL, which may reflect the special immune status of the brain.
authors.affiliation: Département de Neuropathologie, INSERM U360, CNRS URA 625, CHU Pitié-Salpêtrière, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Camilleri-Broët
authors.forename: F
authors.initials: F
authors.lastname: Davi
authors.forename: J
authors.initials: J
authors.lastname: Feuillard
authors.forename: D
authors.initials: D
authors.lastname: Seilhean
authors.forename: J F
authors.initials: JF
authors.lastname: Michiels
authors.forename: P
authors.initials: P
authors.lastname: Brousset
authors.forename: B
authors.initials: B
authors.lastname: Epardeau
authors.forename: E
authors.initials: E
authors.lastname: Navratil
authors.forename: K
authors.initials: K
authors.lastname: Mokhtari
authors.forename: C
authors.initials: C
authors.lastname: Bourgeois
authors.forename: L
authors.initials: L
authors.lastname: Marelle
authors.forename: M
authors.initials: M
authors.lastname: Raphäel
authors.forename: J J
authors.initials: JJ
authors.lastname: Hauw
mesh_terms: D000328:Adult; D000956:Antigens, Viral / Q000378:metabolism; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology*; D019309:Epstein-Barr Virus Nuclear Antigens / Q000378:metabolism; D005260:Female; D005838:Genotype; D004854:Herpesvirus 4, Human / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D017403:In Situ Hybridization; D016483:Lymphoma, AIDS-Related / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009857:Oncogenes; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc; D012367:RNA, Viral / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D014763:Viral Matrix Proteins / Q000378:metabolism
chemical_list: D000956:Antigens, Viral; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D019309:Epstein-Barr Virus Nuclear Antigens; C099537:Epstein-Barr virus encoded RNA 1; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc; D012367:RNA, Viral; D016159:Tumor Suppressor Protein p53; D014763:Viral Matrix Proteins